Gilead Sciences Inc
XHAM:GIS

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
XHAM:GIS
Watchlist
Price: 105.78 EUR -0.02% Market Closed
Market Cap: 131.8B EUR

Intrinsic Value

The intrinsic value of one GIS stock under the Base Case scenario is 103.02 EUR. Compared to the current market price of 105.78 EUR, Gilead Sciences Inc is Overvalued by 3%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GIS Intrinsic Value
103.02 EUR
Overvaluation 3%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Gilead Sciences Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about GIS?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is GIS valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Gilead Sciences Inc.

Explain Valuation
Compare GIS to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Gilead’s heavy reliance on its HIV portfolio could hinder long-term growth if new competitive therapies and emerging generics erode market share faster than forecast, putting pressure on revenues and margins.

Despite significant investments in oncology, some of Gilead’s pipeline candidates have faced setbacks, raising doubts about the company’s ability to diversify beyond its core antivirals and deliver strong returns on high-cost acquisitions.

Stagnating sales in the hepatitis C segment, amplified by intensified competition and price pressures, may challenge management’s efforts to sustain overall top-line growth and maintain investor confidence.

Bull Theses

Gilead’s robust HIV franchise, led by Biktarvy, continues to post solid growth and enjoy strong patent protection, providing a stable revenue base and healthy cash flow to fund R&D and strategic acquisitions.

The company’s expanding oncology pipeline, bolstered by acquisitions like Kite Pharma and Immunomedics, offers potential for long-term diversification as novel cell and targeted therapies begin to gain traction in large cancer markets.

Gilead’s consistent free cash flow generation affords management the flexibility to pursue strategic partnerships and invest aggressively in innovative therapeutic areas, positioning the firm ahead of rivals seeking to build similar franchises.

Show More Less
How do you feel about GILD?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Gilead Sciences Inc

Current Assets 18.8B
Cash & Short-Term Investments 9.4B
Receivables 5.1B
Other Current Assets 4.4B
Non-Current Assets 39.7B
PP&E 5.5B
Intangibles 26.3B
Other Non-Current Assets 7.9B
Current Liabilities 12.3B
Other Current Liabilities 12.3B
Non-Current Liabilities 24.8B
Other Non-Current Liabilities 24.8B
Efficiency

Free Cash Flow Analysis
Gilead Sciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Gilead Sciences Inc

Revenue
29.1B USD
Cost of Revenue
-6.2B USD
Gross Profit
22.9B USD
Operating Expenses
-11.6B USD
Operating Income
11.3B USD
Other Expenses
-3.2B USD
Net Income
8.1B USD
Fundamental Scores

GIS Profitability Score
Profitability Due Diligence

Gilead Sciences Inc's profitability score is 66/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
Exceptional Operating Margin
ROE is Increasing
Exceptional Gross Margin
66/100
Profitability
Score

Gilead Sciences Inc's profitability score is 66/100. The higher the profitability score, the more profitable the company is.

GIS Solvency Score
Solvency Due Diligence

Gilead Sciences Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Low D/E
High Altman Z-Score
Long-Term Solvency
Short-Term Solvency
63/100
Solvency
Score

Gilead Sciences Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GIS Price Targets Summary
Gilead Sciences Inc

Wall Street analysts forecast GIS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GIS is 116.6 EUR with a low forecast of 91.35 EUR and a high forecast of 138.38 EUR.

Lowest
Price Target
91.35 EUR
14% Downside
Average
Price Target
116.6 EUR
10% Upside
Highest
Price Target
138.38 EUR
31% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for GILD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

GILD Insider Trading
Buy and sell transactions by insiders

GIS News

Other Videos
What is the Intrinsic Value of one GIS stock?

The intrinsic value of one GIS stock under the Base Case scenario is 103.02 EUR.

Is GIS stock undervalued or overvalued?

Compared to the current market price of 105.78 EUR, Gilead Sciences Inc is Overvalued by 3%.

Back to Top